Virtual Research Symposium

symposium

We are excited to invite you to participate in our UFHCC Virtual Research Symposium, to be held on Dec. 8-10, 2020.

You can now pre-register for the following symposium events:

Virtual Poster Session

Keynote Speaker

Trainee Award Presentations

Please note that you will need to register with your ufl email address to view the posters and the trainee award presentations.


Symposium Schedule

Virtual Poster Session

Tuesday, December 8, 2020 — 4-6 p.m. EDT

The UFHCC recognizes the importance of providing a forum for our trainees to showcase your research and we are excited to welcome you to our first ever Virtual Poster Session.

UFHCC VIRTUAL RESEARCH SYMPOSIUM

Important Information for Poster Presenters

Each presenter will have a page with your poster title, name, faculty mentor’s name, abstract, a PDF of your poster and a three-minute video presentation summarizing your poster.


Keynote Speaker

Lecture title: Making Impact: Cancer Centers in the 21st Century

Wednesday, December 9, 2020 — 12-1 p.m. EDT

Robert Winn, M.D., was appointed director of the Massey Cancer Center at Virginia Commonwealth University in Richmond, Virginia in December 2019. In this position, he oversees a cancer center designated by the National Cancer Institute that provides outstanding cancer care, conducts groundbreaking research to discover new treatments for cancer and offers high-quality education, training and community outreach programs.

Headshot of Dr. Winn, Director of the VCU Massey Cancer Center
Dr. Robert Winn
Director, VCU Massey Cancer Center; Professor, Division of Pulmonary Disease and Critical Care Medicine,
VCU School of Medicine

Dr. Winn is committed to community-engaged research centered on eliminating health disparities. He is a principal investigator on several community-based projects funded by the NIH and National Cancer Institute, including the All of Us Research Program, a NIH precision medicine initiative. He has received national and international acclaim for his efforts to empower underserved patient populations, improve health care delivery and ensure equal access to cancer care.

The recipient of numerous awards and honors, Dr. Winn was awarded the National Cancer Institute Center to Reduce Cancer Health Disparities CURE Program Lifetime Achievement Award. He is a member of the National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine and of several other professional societies. Dr. Winn holds a B.A. from the University of Notre Dame and an M.D. from the University of Michigan Medical School in Ann Arbor. He completed an internship and residency in internal medicine at Rush-Presbyterian-St. Luke’s Medical Center in Chicago and a fellowship in pulmonary and critical care medicine at the University of Colorado Health Sciences Center in Denver.


UFHCC Trainee Award Presentations: Celebrating our 2019/2020 UFHCC Awardees

Thursday, December 10, 2020 — 4-5:30 p.m. EDT

The UF Health Cancer Center awards up to five graduate students every year to recognize and support outstanding predoctoral candidates who are conducting innovative cancer research. Awardees will give a three-minute thesis presentation at the Cancer Center’s Virtual Research Symposium.

2020 Awardees – To be announced!

2019 Awardees

  • Bayli DiVita Dean
    Mentor: Catherine Flores, Ph.D.
    Elucidating the role of gliomas on hematopoietic cells
  • Abdelrahman Elsayed
    Mentor: Jatinder Lamba, Ph.D.
    Genome Wide and Targeted Approaches to Identify Biomarkers Associated with Clinical Outcomes in Pediatric AML Patients
  • Adaixa Padron
    Mentor: Deidre Pereira, Ph.D.
    Diurnal Variations in Salivary Concentrations of Pro-Tumorigenic Cytokines and Possible Effects of Psycho-Physiological Stress in Oncology Patients and Matched Healthy Controls
  • Mai Tanaka
    Mentor: Dietmar Siemann, Ph.D.
    Multimodal roles of Axl in Cancer Metastasis
  • Kartika Venugopal
    Mentor: Olga Guryanova, M.D., Ph.D.
    Leukemia-associated DNMT3A mutant cells are more sensitive to replication stalling pharmacological agents